Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Colorectal Neoplasms 1

Interventions

Cisplatin 43Radiotherapy 27Radiotherapy, Intensity-Modulated 24Radiation 16Carboplatin 14Surveys and Questionnaires 13Magnetic Resonance Spectroscopy 13Cetuximab 11Surgical Procedures, Operative 10pembrolizumab 9Specimen Handling 8Chemoradiotherapy 8Drug Therapy 7Docetaxel 7Biopsy 71,2-diaminocyclohexaneplatinum II citrate 7Platinum 6Paclitaxel 6Fluorouracil 6durvalumab 5X-Rays 5Observation 5Blood Specimen Collection 5Standard of Care 4Nivolumab 4Immunohistochemistry 4Celecoxib 4Taxes 3Neck Dissection 3Liquid Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oropharyngeal Neoplasms × utomilumab × Clear all
NCT03258008 2022-12-16

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡